Heart disease and diabetes markers to complement VAP advanced cholesterol profile
ORLANDO, Fla. and BIRMINGHAM, Ala., March 30 /PRNewswire/ -- Atherotech, Inc., developer of the VAP Cholesterol Test, has announced the addition of new cardiovascular and metabolic testing panels at ACC.09, the American College of Cardiology (ACC) 58th Annual Scientific Session Exposition. Atherotech is adding more than a dozen new tests, including C-Reactive Protein (hsCRP), ApoE genotype, and NT-proBNP, for assessment of patients at intermediate to high risk of cardiometabolic diseases. The company is also adding advanced and follow-up cardiovascular disease (CVD) risk profiles.
"We're maximizing the value of our core VAP technology with additional cardiometabolic tests," said Atherotech President Michael Mullen. "This provides physicians and cardiology practices with a single source for the VAP Cholesterol Test plus the new test panels. You get the complete cardiovascular and metabolic view."
Atherotech representatives will be available to discuss the VAP Cholesterol Test and new test panels in booth #1263, and blood draws will be provided to qualified attendees during exhibit hours March 29-31. Because LDL is directly measured, fasting is not required. Test results will be returned via mail after the conference.
The VAP Test, which recently added apoAI (and the apoB/apoAI ratio) to its panel, uses advanced lipid profile testing in the identification of individuals at increased risk of heart disease. The new test panels enable Atherotech to increase its scientific and diagnostic capabilities by offering much more complete cardiometabolic testing.
Steven Margolis, M.D., FAAFP, DABCL, a board-certified lipidologist who currently uses the VAP Test for advanced lipid testing of patients in his Sterling Heights, Mich., practice, says the new testing panels add significant benefits for practices
|SOURCE Atherotech, Inc.|
Copyright©2009 PR Newswire.
All rights reserved